babies

New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV

...fects of PREZISTAon pregnant women or their unborn babies are not known. In the pooled analysis of POWER 1 and 2 studies, the mostfrequently reported drug-related adverse events of at leastmoderate to severe intensity in patients receivingPREZISTA/r-containing regimen were headache (3.8 percent), diarrhea(...

Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric Academic Societies' Annual Meeting

... at the 28th day of life or 36 weeks PMA.Premature babies are often born with a lack of natural lungsurfactant and are unable to absorb sufficient oxygen, resulting inRDS. These infants often require endotracheal intubation toadminister one of the currently available animal-derivedsurfactants (usually withi...

Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies

... bothgroups, death rates were nearly 20% lower for babies treated withporactant alfa than for those treated ...ound a significantly higher survival rateamong RDS babies treated with poractant alfa at an initial dose of200 mg/kg than with beractant. Results from this la...

Study Supports Cost-Effectiveness of Medtronic's Spasticity Treatment for Children with Cerebral Palsy

... to United Cerebral Palsy, with approximately8,000 babies and 1,200 to 1,500 preschool-age children diagnosedwith the condition each year. Caused by damage to one or more areasof the developing brain, cerebral palsy is characterized by aninability to control motor function fully, particularly musclecontrol ...

Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth

... group that suffers the largest numberof premature babies each year," said Robert S. Mills, president andchief executive officer of Columbia Laboratories. "We are planningto meet with the FDA in the coming months to explore the potentialclinical and regulatory path for PROCHIEVE 8% to prevent pretermbirth i...